Cognizant Collaborates with Medidata to Provide Specialized Support for Life Sciences Clients
Rhea-AI Summary
Cognizant (CTSH) has announced an expanded partnership with Medidata, a Dassault Systèmes brand specializing in clinical trial solutions. The multi-year renewal agreement focuses on providing enhanced support for Medidata's life sciences clients through a dedicated team of platform specialists serving pharmaceutical, biotech, medical device, and contract research organizations.
The collaboration aims to maximize Medidata's value proposition by improving user satisfaction and streamlining clinical trial development. Key aspects include customer success, patient service desk, implementation, engineering, integrations, and user acceptance testing services. The partnership will leverage Medidata's AI-powered technologies, including Clinical Data Studio, Health Record Connect, and myMedidata patient portal, combined with Cognizant's network of Medidata Certified Services Professionals.
Positive
- Strategic expansion of partnership with industry leader Medidata strengthens Cognizant's position in life sciences sector
- Multi-year renewal agreement provides stable, long-term revenue stream
- Access to advanced AI-powered technologies enhances service offerings
Negative
- None.
Insights
The expanded partnership between Cognizant and Medidata marks a significant strategic advancement in the $50+ billion clinical trials technology market. This collaboration strengthens Cognizant's position in the lucrative life sciences technology sector through several key mechanisms:
The partnership leverages three critical market trends: 1) The increasing demand for AI-powered clinical trial solutions, 2) The growing need for integrated clinical data management platforms and 3) The industry-wide push for improved trial efficiency and patient outcomes. By providing dedicated Medidata Platform specialists and expanding access to AI-powered technologies, Cognizant positions itself to capture a larger share of the clinical trial technology services market.
The multi-year renewal agreement has particular significance in the context of rising R&D costs in the pharmaceutical industry, where clinical trials typically account for 40-60% of R&D budgets. By offering comprehensive support services - from implementation to user acceptance testing - Cognizant establishes recurring revenue streams while deepening its relationship with life sciences clients.
The focus on Medidata's advanced platforms, including Clinical Data Studio and Health Record Connect, aligns with the industry's digital transformation trajectory. This positions Cognizant advantageously in the rapidly growing market for AI-enabled clinical trial solutions, expected to grow at a CAGR of 15-20% through 2028.
The organizations plan to support clients through expanded partnership and offer broader access to Medidata's AI-powered technologies to accelerate clinical trial development
As part of the multi-year renewal agreement, Cognizant is providing a dedicated team of Medidata Platform specialists to support their clients in pharmaceutical, biotech, medical device, contract research organizations, and patients using Medidata services. The goal is to maximize Medidata's value for life sciences clients. The collaboration aims to improve the experience for Medidata's users, enabling their clients to focus on clinical trial development and improving patient outcomes.
"Our partnership with Cognizant represents a shared commitment to transforming clinical research through innovation and expertise," said Janet Butler, EVP, Head of Global Sales, of Medidata. "By combining Medidata's advanced AI-driven technologies with Cognizant's deep industry knowledge and operational excellence, we support life sciences organizations to streamline their R&D efforts, derive actionable insights from complex data, and ultimately bring life-changing therapies to patients more efficiently."
Cognizant and Medidata are deepening their multi-year collaboration with the goal to accelerate clinical trial development by expanding access to Medidata's AI-powered technologies. When combined with Medidata Clinical Data Studio, Medidata Health Record Connect, and the myMedidata patient portal, these solutions are helping to transform R&D with tailored patient, site, and data experiences. As a top Global Medidata Strategic Alliance Partner, Cognizant is leveraging its extensive network of Medidata Certified Services Professionals to help life sciences organizations modernize clinical operations and data management.
"We are thrilled to accelerate our work with Medidata to help mutual clients leverage next-generation AI-enabled clinical capabilities on the unified Medidata Platform," said Mohammad Haque, SVP, Global Large Deals Lead and Business Unit Head, Life Sciences, of Cognizant. "Our collaboration aims to unlock the full potential of clients' clinical data and processes, improving user satisfaction and empowering them to make better-informed decisions faster for improved patient outcomes."
About Cognizant
Cognizant (Nasdaq: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we're improving everyday life. See how at www.cognizant.com or @cognizant.
For more information, contact:
Natalie Steffen
Natalie.Steffen@cognizant.com
300 Frank W. Burr Blvd. Suite 36, 6th Floor
+1 201 801 0233 Cognizant.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cognizant-collaborates-with-medidata-to-provide-specialized-support-for-life-sciences-clients-302363839.html
SOURCE Cognizant Technology Solutions Corporation
FAQ
What is the purpose of Cognizant's expanded partnership with Medidata?
What services will CTSH provide under the new agreement?
How will this partnership benefit Medidata's clients?
What specific Medidata technologies will be utilized in this partnership?
How will CTSH support Medidata's platform implementation?
